These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
1456 related articles for article (PubMed ID: 34256754)
21. Development and validation of a robust immune-related prognostic signature in early-stage lung adenocarcinoma. Wu P; Zheng Y; Wang Y; Wang Y; Liang N J Transl Med; 2020 Oct; 18(1):380. PubMed ID: 33028329 [TBL] [Abstract][Full Text] [Related]
22. Identification of a methylomics-associated nomogram for predicting overall survival of stage I-II lung adenocarcinoma. Wang H; Wei C; Pan P; Yuan F; Cheng J Sci Rep; 2021 May; 11(1):9938. PubMed ID: 33976305 [TBL] [Abstract][Full Text] [Related]
23. A Prognostic 14-Gene Expression Signature for Lung Adenocarcinoma: A Study Based on TCGA Data Mining. Liu J; Hou S; Wang J; Chai Z; Hong X; Zhao T; Sun Z; Bai L; Gao H; Gao J; Chen G Oxid Med Cell Longev; 2020; 2020():8847226. PubMed ID: 33414898 [TBL] [Abstract][Full Text] [Related]
24. A ten-gene signature-based risk assessment model predicts the prognosis of lung adenocarcinoma. Jiang H; Xu S; Chen C BMC Cancer; 2020 Aug; 20(1):782. PubMed ID: 32819300 [TBL] [Abstract][Full Text] [Related]
25. Molecular subtypes of lung adenocarcinoma patients for prognosis and therapeutic response prediction with machine learning on 13 programmed cell death patterns. Wei Q; Jiang X; Miao X; Zhang Y; Chen F; Zhang P J Cancer Res Clin Oncol; 2023 Oct; 149(13):11351-11368. PubMed ID: 37378675 [TBL] [Abstract][Full Text] [Related]
26. Comprehensive analysis of a novel signature incorporating lipid metabolism and immune-related genes for assessing prognosis and immune landscape in lung adenocarcinoma. Wang Y; Xu J; Fang Y; Gu J; Zhao F; Tang Y; Xu R; Zhang B; Wu J; Fang Z; Li Y Front Immunol; 2022; 13():950001. PubMed ID: 36091041 [TBL] [Abstract][Full Text] [Related]
27. Bioinformatics analysis of an immunotherapy responsiveness-related gene signature in predicting lung adenocarcinoma prognosis. Jiang Y; Hammad B; Huang H; Zhang C; Xiao B; Liu L; Liu Q; Liang H; Zhao Z; Gao Y Transl Lung Cancer Res; 2024 Jun; 13(6):1277-1295. PubMed ID: 38973963 [TBL] [Abstract][Full Text] [Related]
28. FKBP3, a poor prognostic indicator, promotes the progression of LUAD via regulating ferroptosis and immune infiltration. Li S; Yang L; Li J Medicine (Baltimore); 2024 Jun; 103(26):e38606. PubMed ID: 38941396 [TBL] [Abstract][Full Text] [Related]
29. Establishment and validation of an immune-associated signature in lung adenocarcinoma. Wang Z; Chen X Int Immunopharmacol; 2020 Nov; 88():106867. PubMed ID: 32799112 [TBL] [Abstract][Full Text] [Related]
30. A Recurrence-Specific Gene-Based Prognosis Prediction Model for Lung Adenocarcinoma through Machine Learning Algorithm. Xu S; Zhou J; Liu K; Chen Z; He Z Biomed Res Int; 2020; 2020():9124792. PubMed ID: 33224985 [TBL] [Abstract][Full Text] [Related]
31. Profiles of immune infiltration in lung adenocarcinoma and their clinical significant: A gene-expression-based retrospective study. Chen G; Dong Z; Wu D; Chen Y J Cell Biochem; 2020 Nov; 121(11):4431-4439. PubMed ID: 32003059 [TBL] [Abstract][Full Text] [Related]
32. RNA-seq and bulk RNA-seq data analysis of cancer-related fibroblasts (CAF) in LUAD to construct a CAF-based risk signature. Si Y; Zhao Z; Meng X; Zhao K Sci Rep; 2024 Oct; 14(1):23243. PubMed ID: 39369095 [TBL] [Abstract][Full Text] [Related]
33. New molecular insights into ferroptosis in lung adenocarcinoma progression and pharmacological compounds for targeted therapy. Tian W; Wan X; Tian L; Wu Y; Cui X; Yi J J Gene Med; 2024 Jan; 26(1):e3579. PubMed ID: 37581210 [TBL] [Abstract][Full Text] [Related]
34. Dysregulated ferroptosis-related genes indicate potential clinical benefits for anti-PD-1/PD-L1 immunotherapy in lung adenocarcinoma. Zhou M; Zhang X; Li T; Chen Y J Clin Lab Anal; 2021 Dec; 35(12):e24086. PubMed ID: 34752672 [TBL] [Abstract][Full Text] [Related]
35. Construction of a prognostic model for non-small-cell lung cancer based on ferroptosis-related genes. Han K; Wang J; Qian K; Zhao T; Liu X; Zhang Y Biosci Rep; 2021 May; 41(5):. PubMed ID: 33988228 [TBL] [Abstract][Full Text] [Related]
36. Pan-Cancer Analysis of Immune Cell Infiltration Identifies a Prognostic Immune-Cell Characteristic Score (ICCS) in Lung Adenocarcinoma. Zuo S; Wei M; Wang S; Dong J; Wei J Front Immunol; 2020; 11():1218. PubMed ID: 32714316 [No Abstract] [Full Text] [Related]
37. Construction of the optimization prognostic model based on differentially expressed immune genes of lung adenocarcinoma. Zhai Y; Zhao B; Wang Y; Li L; Li J; Li X; Chang L; Chen Q; Liao Z BMC Cancer; 2021 Mar; 21(1):213. PubMed ID: 33648465 [TBL] [Abstract][Full Text] [Related]
38. Identification of critical ferroptosis regulators in lung adenocarcinoma that RRM2 facilitates tumor immune infiltration by inhibiting ferroptotic death. Tang B; Xu W; Wang Y; Zhu J; Wang H; Tu J; Weng Q; Kong C; Yang Y; Qiu R; Zhao Z; Xu M; Ji J Clin Immunol; 2021 Nov; 232():108872. PubMed ID: 34648954 [TBL] [Abstract][Full Text] [Related]
39. A novel transcriptomic signature associated with lymphovascular invasion predicts clinical outcomes, tumor microenvironment, and therapeutic response in lung adenocarcinoma. Huang X; Feng Y; Li Y; Ding H; Huang X; Chen C; Yu Z; Zhang J; Xu X; Ma D; Yu S; Chen C Int Immunopharmacol; 2024 Jan; 127():111286. PubMed ID: 38064818 [TBL] [Abstract][Full Text] [Related]
40. Prognostic value and immune infiltration of a novel stromal/immune score-related P2RY12 in lung adenocarcinoma microenvironment. Yu L; Cao S; Li J; Han B; Zhong H; Zhong R Int Immunopharmacol; 2021 Sep; 98():107734. PubMed ID: 34175738 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]